AGNC vs AMH

AGNC exhibits severe financial health concerns, as evidenced by a Piotroski F-Score of 3/9 (indicating weak fundamentals) and a missing Altman Z-Score, which raises unquantified distress risk. Despite a high intrinsic value estimate of $43.37 and a Graham Number of $17.64, the stock trades at $10.23, suggesting a potential undervaluation—however, this is undermined by extreme leverage (Debt/Equity: 6.89), near-zero liquidity (Current Ratio: 0.18), and a 97.96% payout ratio. The recent insider selling of $11.43M over six months signals strong bearish sentiment, while earnings have consistently missed expectations in the last four quarters. The 52-week range of $7.85–$12.19 reflects high volatility and lack of sustained momentum.

AMH exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. Despite strong recent earnings surprises and solid revenue growth, elevated valuation metrics (P/E of 26.66, Forward P/E of 39.94) and a concerning 98.31% dividend payout ratio raise sustainability concerns. Insider selling and a bearish technical trend counterbalance positive analyst sentiment, while the stock trades above the Graham Number of $22.83 but near the intrinsic value of $35.40. The company's profitability is solid, but ROE and ROIC are constrained by sector dynamics and leverage.